Record Performances in U.S. Orthopedics and 7D Unit Placements
Orthofix achieved record performances in U.S. orthopedics sales and matched the highest number of 7D unit placements in any quarter to date.
Strong Financial Performance
The company reported net sales of $196.6 million, a 7% year-over-year growth on a constant currency basis, and achieved positive free cash flow of $5.9 million.
U.S. Spine Fixation Growth
U.S. spine fixation revenue grew 18%, more than triple the market rate, driven by strong demand for new products like Reef and WaveForm interbody products.
Bone Growth Therapies Growth
The Bone Growth Therapies segment grew 9% overall, with 13% growth in the fracture market.
Refinancing to Support Growth
Orthofix successfully completed a new $275 million financing to replace its existing credit facility, optimizing its capital structure for long-term growth.
Introduction of New Financial Targets
Orthofix introduced new 2027 financial targets, projecting mid-teens non-GAAP adjusted EBITDA as a percent of net sales and positive free cash flow from 2025 to 2027.